{"id":113177,"date":"2026-06-21T12:03:45","date_gmt":"2026-06-21T12:03:45","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/113177\/"},"modified":"2026-06-21T12:03:45","modified_gmt":"2026-06-21T12:03:45","slug":"novo-nordisk-owner-to-open-obesity-drug-incubators-across-europe","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/113177\/","title":{"rendered":"Novo Nordisk Owner to Open Obesity Drug Incubators Across Europe"},"content":{"rendered":"<p class=\"ArticleBodyText_articleBodyContent__17wqE typography_articleBody___5jDr\" data-component=\"paragraph\">The primary owner of Ozempic maker Novo Nordisk A\/S is launching a network of research incubators across Europe, seeking to create breakthrough obesity and diabetes treatments by turning academic discoveries into commercial ventures.<\/p>\n<p class=\"ArticleBodyText_articleBodyContent__17wqE typography_articleBody___5jDr\" data-component=\"paragraph\">The CardioMetabolic Bridge program will open its first location in London this month, followed by sites in Italy and Germany later this year, according to a statement from the <a href=\"https:\/\/www.bloomberg.com\/quote\/7709927Z:DC\" target=\"_blank\" rel=\"noopener nofollow\" class=\"media-ui-Link_link-tVkXhPLPofs-\" data-component=\"link\">Novo Nordisk Foundation<\/a>, which holds a controlling stake in the Danish drugmaker. <\/p>\n","protected":false},"excerpt":{"rendered":"The primary owner of Ozempic maker Novo Nordisk A\/S is launching a network of research incubators across Europe,&hellip;\n","protected":false},"author":2,"featured_media":113178,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[438,726,174,71,190,159,114,272,13578,21306,4347,591],"class_list":["post-113177","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-business","tag-chief-executive-officer","tag-china","tag-europe","tag-germany","tag-italy","tag-london","tag-novo-nordisk","tag-novo-nordisk-a-s-b","tag-pharmaceutical","tag-science","tag-startups"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116788003157020438","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/113177","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=113177"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/113177\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/113178"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=113177"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=113177"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=113177"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}